BOARD OF DIRECTORS

OxThera is built on a highly experienced and committed team and strong network in oxaluria research, rare disease drug development and anaerobic bacterial manufacturing.

Board of Directors

Georges Gemayel
Chairman

Martijn Kleijwegt

Rémi Droller

Lance Berman

Sten Verland

Maarten de Chateau

Jonas Brambeck

Alain Munoz

Anders Fink Vadsholt

Kirsti Gjellan

Georges Gemayel, Chairman

Born 1960. Chairman of the board since 2014.
Education: PhD in Pharmacology from Universite Paris-Sud.
Other current assignments: Chairman of the board of
directors of Orphazyme, Enterome Bioscience and Dynacure.
Member of the board of directors of Supernus Pharmaceuticals,
Momenta Pharmaceuticals and St. Andrew’s School in Ngong
Inc.
Previous assignments (last five years): Chairman of the board
of directors of Dimension Therapeutics, EpiTherapeutics
and Vascular Magnetics Inc. Member of the board of
directors of International Institute of New England, Raptor
Pharmaceuticals, NPS Pharmaceuticals and Prosensa.
Independent of The Company and executive
management/The major Shareholders: 
Yes/Yes
Shareholding in the Company: Georges Gemayel holds
5,309,147 Class A Options in the Company.

Martijn Kleijwegt

Born 1955. Board member since 2016.
Education: Master’s Degree in Economics from University of
Amsterdam.
Other current assignments: Director and Managing Partner
at various LSP Management and other LSP group companies.
Director at Arvelle Therapeutics, Eloxx and Orphazyme.
Supervisory Director at Pharvaris and Kiadis Pharma.
Previous assignments (last five years): Supervisory Director at
Prosensa.
Independent of The Company and executive
management/The major Shareholders
: Yes/No
Shareholding in the Company: Martijn Kleijwegt holds no
shares in the Company.

Rémi Droller

Born 1975. Board member since 2016.
Education: Master’s Degree in Molecular Biology from
University Pierre et Marie Curie University, Paris. Master’s
Degree in Financing and Innovation management from
AgroParisTech.
Other current assignments: Managing Partner at Kurma
Partners SA á Directoire. Member of the Supervisory board
and member of the board of directors of AM Pharma SARL
(BV), Pharvaris SARL (BV) and Orphazyme. Member of the
Supervisory board of Dynacure SAS, Vico Therapeutics
Imcheck SAS and Flamingo Therapeutics BV.
Previous assignments (last five years): Member of the
Supervisory board and member of the board of directors of
Stat Dx SARL (SL). Chairman of the Supervisory Board of Step
Pharma and Corlieve Therapeutics.
Independent of The Company and executive
management/The major Shareholders
: Yes/No
Shareholding in the Company: Rémi Droller holds no shares in
the Company.

Lance Berman

Born 1970. Board member since 2018.
Education: MB.ChB from University of Cape Town Medical
School. MSc in Pharmaceutical Medicine from Hibernia
College.
Other current assignments: Chief Medical Officer at
Pulmocide Ltd.
Previous assignments (last five years): Chief Medical Officer
at Relypsa, Inc (USA) and CPEX Pharmaceuticals (USA). Chief
Medical Officer at AELIX Therapeutics.
Independent of The Company and executive
management/The major Shareholders
: Yes/No
Shareholding in the Company: Lance Berman holds no shares
in the Company.

Sten Verland

Born 1957. Board member since 2016.
Education: PhD in Immunology from University of
Copenhagen. MSc in Biology and Mathematics from University
of Copenhagen.
Other current assignments: Member of the board of directors
and General Partner at Sunstone Capital Life Science Ventures
A/S. Member of the board of management of Sunstone LSV
Special Limited Partner IV ApS, Sunstone LSV General Partner
IV ApS, Sunstone LSV Invest III Holding A/S, Sunstone LSV
General Partner I ApS, Sunstone LSV General Partner II
ApS, Sunstone LSV General Partner III ApS, Sunstone LSV
Invest III ApS, Sunstone LSV Special Limited Partner III
ApS, Sunstone LSV Special Limited Partner II ApS, Sunstone
LSV Invest II ApS, Sunstone LSV Special Limited Partner III
Holding ApS, Heartcore (LSV) Special Limited Partner II ApS
and GENOBIOTIX ApS. Member of the board of directors of
Sunstone Capital A/S, Sunstone LSV Partners Holding ApS,
Sunstone LSV Partners & Co. Holding, Sunstone LSV GP BI
Holding ApS, Sunstone LSV General Partner BI ApS, Skovlyst
Production A/S, Minervax ApS, Orphazyme ApS, Anergis
SA, Vaximm AG, Sunstone LSV Partners & Co Holding Aps,
Sunstone LSV GP I Holding ApS, Sunstone LSV Invest II Holding
ApS and Sunstone LSV Special LP II Holding ApS. Managing
Director at Verland Holding ApS, Verland Holding II ApS and
VERLAND CAPITAL ApS.
Previous assignments (last five years): General Partner
at Sunstone LSV Management A/S. Member of the board of
management of LSV & Co. Special Limited Partner III Holding
ApS, Sunstone LSV & Co. Invest III Holding ApS, Sunstone
LSV Special Limited Partner III Holding ApS, Sunstone LSV
Invest III Holding ApS, Sunstone LSV Partner & Co. Holding
III ApS and Sunstone LSV Partners Holding III ApS. Member
of the board of directors of Sunstone LSV General Partner
I ApS, Sunstone LSV General Partner II ApS, P/S Sunstone
Biomedicinsk Venture III, Biovision A/S, NsGene A/S, F2G Ltd.,
Stemcare A/S and Rigontec GmbH. Director and member of the
board of directors of VetVerland ApS.
Independent of The Company and executive
management/The major Shareholders
: Yes/No
Shareholding in the Company: Sten Verland holds no shares in
the Company.

Maarten de Chateau

Born 1963. Board member since 2016.
Education: M.D. and Ph.D from Lund University.
Other current assignments: Chairman of the board of
directors of Atrogi AB. Member of the board of directors of
Beactica Therapeutics AB, Cavis Technologies AB, Chateau
Holding AB, Amarna Holding AB and Gesynta Pharma AB.
Gesynta Pharma AB. CEO and member of the board of directors
of Buzzard Pharmaceuticals AB and Cordivest AB. External
CEO at Sixera Pharma AB. Deputy member of the board of the
directors of Saare Consulting AB.
Previous assignments (last five years): VP of Camurus AB.
CEO and member of the board of directors of Cormorant
Pharmaceuticals AB. Member of the board of directors of
Addbio AB and Evident Life AB. Deputy member of the board of
directors of Nylof Holding AB.
Independent of The Company and executive
management/The major Shareholders
: Yes/Yes
Shareholding in the Company: Maarten de Chateau holds no
shares in the Company.

Jonas Brambeck

Born 1958. Board member since 2012.
Education: Master of Science from Royal Institute of
Technology in Stockholm. PhD in Organic Chemistry from
Royal Institute of Technology in Stockholm.
Other current assignments: Member of the board of directors
of Oncopeptides AB and OxThera Intellectual Property AB.
Deputy member of the board of directors of Avidicare Holding
AB, Airsonett AB and AirSonett Holding AB. Investment
director at Industrifonden.
Previous assignments (last five years): Member of the board
of directors of Ascelia Pharma AB, Athera Biotechnologies AB,
RSPR Pharma AB and Oveun AB. Deputy member of the board
of directors of Glionova AB. Holder of SYNTHETIA.
Independent of The Company and executive
management/The major Shareholders
: Yes/No
Shareholding in the Company: Jonas Brambeck holds no
shares in the Company.

Alain Munoz

Born 1949. Board member since 2018.
Education: Medical Degree in Qualified Cardiology and
Intensive Care from Montpellier University.
Other current assignments: Chairman of the board of
directors of Hybrigenics. Supervisory member of the board
of directors of Valneva SA. Member of the board of directors
of Zealand Pharma, Auris Médical and Amryt Pharma plc.
President at SBM.
Previous assignments (last five years): Member of the board
of directors of Genticel. Chariman of the board of directors of
Hybrigenics.
Independent of The Company and executive
management/The major Shareholders
: Yes/Yes
Shareholding in the Company: AlainMunoz holds 1,805,110
Class A Options in the Company.

Anders Fink Vadsholt

Born 1969. Board member since 2019.
Education: MBA, Strategy and Finance, Melbourne University,
Master of Science, MS, Commercial Law and Economics
Copenhagen Business School.
Other current assignments: CFO at Orphazyme A/S. Director
at Alpha Healthcare Investments. Partner at Obton Solenergi
Sinope Komplementaranpartsselskab.
Previous assignments (last five years): Co-Founder and
Partner at Copenhagen Innovation. Co-Founder & Partner of
Lakeside Invest ApS. Capital Management ApS and Lakeside
Invest ApS.
Independent of The Company and executive
management/The major Shareholders:
Yes/Yes
Shareholding in the Company: Anders Fink Vadsholt holds
796,372 Class B Options in the Company.

Kirsti Gjellan

Born 1963. Board member since 2020.
Education: Master of Science in Pharmacy, University of Oslo.
PhD in Pharmaceutical Technology, University of Oslo.
Other current assignments: Member of the board of directors
of Bio-Works Technologies AB and Kirsti Gjellan AB.
Previous assignments (last five years): Member of the board of
directors of SwedenBio AB, PiiA and Pfizer Health AB.
Independent of The Company and executive
management/The major Shareholders
: Yes/Yes
Shareholding in the Company: Kirsti Gjellan holds no shares in
the Company.